Francesca Bruce

I am a senior writer at the Pink Sheet, all views expressed are my own.

[Pink Sheet, Citeline Regulatory @PharmaPinkSheet]

German HTA: Clinical Cancer Registries Could Hold Key To Better Comparative Data For Benefit Assessments
https://t.co/0xWgMGVLnk #PinkSheet

[Francesca Bruce @ScripFrancesca]

Lots of interesting sessions today at the DIA Europe 2022 meeting today, looking forward to more tomorrow. @DrugInfoAssn

[Maureen Kenny @ScripRegMaureen]

Take a look at our free-to-view @PharmaPinkSheet report by @ScripFrancesca on the finer points behind the @EMA_News review of @VertexPharma's cystic fibrosis combo Kaftrio. https://t.co/uOfo7QNRYY

[Francesca Bruce @ScripFrancesca]

See why investors are concerned about big prices for advanced therapies https://t.co/tZFm2kPjOw

[Maureen Kenny @ScripRegMaureen]

BC province says it's leading Canada by promoting widespread biosimilar use. Re @JanssenGlobal's Remicade, @PharmaPinkSheet reports 5-10% use rate of biosimilar #infliximab in Canada after 4 years on market vs Norway (98%), UK (90%) & Scotland (85%). $$ https://t.co/ePPFSIJxZt

[Neena Brizmohun @ScripRegNeena]

First application from a drug company for joint health economic assessment under new Swedish/Finnish/Norwegian pilot FINOSE expected soon, says TLV’s Niklas Hedberg #TOPRASym18

[Neena Brizmohun @ScripRegNeena]

EU parliamentary negotiations step up on controversial new regulation for member states to cooperate on HTA. Next vote scheduled for Oct 3. DG SANTE’s Flora Giorgio tells #TOPRASym18 she hopes the text will be finalised during this or the next parliament

[Francesca Bruce @ScripFrancesca]

Indeed, what will they call it? https://t.co/mwSwVBbTIn

[Neena Brizmohun @ScripRegNeena]

Europe's CMDh chair Laura Oliveira Santamaria urges industry to tell us the problems you face in meeting the Brexit deadline so we can find flexible solutions to avoid drug shortages #DIAEurope2018

[Neena Brizmohun @ScripRegNeena]

EMA tells me there's been a big response to its survey from companies on how they are preparing for Brexit. It has info on 90% of drugs subject to the survey; results will be published soon #DIAEurope2018

[Neena Brizmohun @ScripRegNeena]

Interesting session on experience with and lessons learned from EMA's 0070 clinical data publication more than one year after the transparency initiative went live #DIAEurope2018

[Maureen Kenny @ScripRegMaureen]

We need to mitigate medicines #shortages before they happen. Now we're managing them when they happen. That's too late. Maggie Dolan of NHS Commercial Solutions at #RAC18.

[Maureen Kenny @ScripRegMaureen]

2017 was very distressing year in UK in terms of #shortages of generic medicines. "Never seen anything like it," says Maggie Dolan of NHS Commercial Solutions at #RAC18.

[Maureen Kenny @ScripRegMaureen]

Getting senior @NICEcomms official on board @ABPI_UK is a major deal for the UK trade association. There's not a lot Carole Longson doesn't know about #HTA. #pharma https://t.co/SlPJynikgJ

[Francesca Bruce @ScripFrancesca]

Brazil's IP system could get more challenging for pharma companies https://t.co/xcOTahP4Il

[Anju Ghangurde @scripanjug]

Minister Ananth Kumar says India will persuade docs to follow generic prescription rule and also propagate it

[Pink Sheet, Citeline Regulatory @PharmaPinkSheet]

Adaptive Pathways: A Solution For Worried #Payers in Europe 🔓 ➡
https://t.co/ccnbg7ZjdF via @ScripRegNeena

[Scrip, Citeline Commercial @PharmaScrip]

The #ScripAwards is free to enter and open to any research-based #pharmaceutical or #biotech company. https://t.co/1SyZR5lHBo

[Francesca Bruce @ScripFrancesca]

Advances in digital healthcare and a new law could make Brazil a better place to do clinical research https://t.co/ghSCMPMtC9

[Francesca Bruce @ScripFrancesca]

UK passes new legislation to curb excessive drug pricing https://t.co/SaSISnRtQG